Taxol, Paclitaxel
Taxol, Paclitaxel Newswire

Taxol, Paclitaxel Newswire

Comprehensive Real-Time News Feed for Taxol, Paclitaxel (generic).

Results 1 - 20 of 21 in Taxol, Paclitaxel (generic)

  1. Scientists propose attacking bioenergetic metabolism to improve anti-cancer therapiesRead the original story w/Photo

    Yesterday | PhysOrg Weblog

    Cells dividing. Genetic material is shown in blue and mitochondria in red. During this process, the mitochondria are damaged making the cells particularly dependent on glucose as a source of energy.

    Comment?

  2. Oasmia's Paclical Does Well in Head to Head Study with Celgene's AbraxaneRead the original story

    Monday Aug 3 | BioSpace

    Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, announced today the topline findings from a head-to-head comparison study of its lead human cancer product Paclical and Celgene's Abraxane ,which show similar pharmacokinetic profiles. The study was conducted in women with metastatic breast cancer.

    Comment?

  3. Nanospheres Safely Deliver High Chemotherapy Doses in Response to Tumor SecretionsRead the original story

    Jul 20, 2015 | San Diego NewsCape

    Scientists have designed nanoparticles that release drugs in the presence of a class of proteins that enable cancers to metastasize. That is, they have engineered a drug delivery system so that the very enzymes that make cancers dangerous could instead guide their destruction.

    Comment?

  4. Nanospheres safely deliver high chemotherapy doses to attack tumorsRead the original story w/Photo

    Jul 15, 2015 | KurzweilAI.net

    Cancer tumors secrete enzymes are triggered by peptide coatings to slice the coatings open, safely delivering an anti-cancer drug Scientists have engineered a drug delivery system that uses specially designed nanoparticles that release drugs in the presence of a specific enzymes - the very ones that enable cancers to metastasize.

    Comment?

  5. Nanospheres shield chemo drugs, safely release high doses in response to tumor secretionsRead the original story w/Photo

    Jul 15, 2015 | Medical News Today

    Scientists have designed nanoparticles that release drugs in the presence of a class of proteins that enable cancers to metastasize. That is, they have engineered a drug delivery system so that the very enzymes that make cancers dangerous could instead guide their destruction.

    Comment?

  6. Nanospheres shield chemo drugs, safely release high doses in response to tumor secretionsRead the original story w/Photo

    Jul 13, 2015 | EurekAlert!

    Scientists have designed nanoparticles that release drugs in the presence of a class of proteins that enable cancers to metastasize. That is, they have engineered a drug delivery system so that the very enzymes that make cancers dangerous could instead guide their destruction.

    Comment?

  7. Patent Deja vu - Hospira v Genentech and another patent diesRead the original story

    Jun 30, 2015 | IPKat

    There has been a superabundant deluge of patent cases last week, with two decisions from the Court of Appeal and two from the Patents Court. So it is with slight delay that the IPKat comes to the latest decision in the apparently endless Hospira v Genentech saga.

    Comment?

  8. Patent Deja vu - Hospira v Genentech and another patent diesRead the original story

    Jun 30, 2015 | IPKat

    There has been a superabundant deluge of patent cases last week, with two decisions from the Court of Appeal and two from the Patents Court. So it is with slight delay that the IPKat comes to the latest decision in the apparently endless Hospira v Genentech saga.

    Comment?

  9. Organic odysseysRead the original story w/Photo

    Jun 29, 2015 | Chemistry World

    Valuable compounds often come from the strangest places, and in such small concentrations that synthetic chemistry has to step u WaterFrame / Alamy Researchers have long sought to imitate the awesome organic synthesis power exhibited by nature in producing wildly complex molecules. Leading academics and their groups still slave to develop typically elegant, but usually still arduous, procedures for the glory of total synthesis.

    Comment?

  10. Killer plants: A handy guide to the hidden dangers in your gardenRead the original story w/Photo

    Jun 26, 2015 | The Independent

    Note: We do not store your email address but your IP address will be logged to prevent abuse of this feature. Please read our Legal Terms & Policies An inquest into whether a deadly plant was responsible for the mysterious death of a gardener has reached an "open verdict"; the coroner said he could not be certain that Nathan Greenway had come into contact with the monkshood flowers on the Hampshire estate where he was working.

    Comment?

  11. Sorrento Therapeutics And L.A.'s Richest Man Ally, Target Celgene's Blockbuster AbraxaneRead the original story w/Photo

    Jun 8, 2015 | Seeking Alpha

    In a surprise announcement last month, Sorrento is selling Cynviloq to Dr. Soon-Shiong, who is the inventor of Abraxane. Not all relevant details of the deal are known, but it adds credibility to this attack on Abraxane and is a mild negative for Celgene's valuation.

    Comment?

  12. Studies at ASCO Focus on HER2-Positive Breast CancerRead the original story

    Jun 4, 2015 | PressReleasePoint

    Researchers reported findings from several studies focusing on HER2-positive breast cancer during the American Society of Clinical Oncology's annual meeting. The studies focused on an oral therapy, neratinib, being studied in early-stage and metastatic breast cancer, as well as different ways to treat breast cancer that is both HER2- and hormone-positive.

    Comment?

  13. Survival, quality-adjusted survival, and other clinical end points in ...Read the original story

    Jun 2, 2015 | British Journal of Cancer

    We invite you to take part in a survey on your use of Nature Publishing Group journals and their associated websites. At the end of the survey there is a chance to enter a prize draw to win a MacBook Air! Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel Using age-based subgroup data from a randomised Phase-3 clinical trial, nab-PC and sb-PC were compared with respect to overall response rate , overall survival , progression-free survival , quality of life , safety 281).

    Comment?

  14. Excitement Should Build At Sorrento TherapeuticsRead the original story w/Photo

    May 5, 2015 | Seeking Alpha

    Conkwest is developing cancer-killing cell therapy to treat patients suffering from lung cancer, leukemia, lymphoma, and other types of cancers. Investors have been patiently waiting for an update from San Diego, California-based Sorrento Therapeutics on its pharmacokinetic data regarding its highly anticipated TRIBECA registrational trial of Cynviloq vs. Abraxane.

    Comment?

  15. Excitement Should Build At Sorrento TherapeuticsRead the original story w/Photo

    May 5, 2015 | Seeking Alpha

    Investors have been patiently waiting for an update from San Diego, California-based Sorrento Therapeutics on its pharmacokinetic data regarding its highly anticipated TRIBECA registrational trial of Cynviloq vs. Abraxane. As you may recall, Abraxane is FDA approved for use in metastatic breast cancer, advanced non-small cell lung cancer and advanced pancreatic cancer.

    Comment?

  16. Oasmia's Lead Cancer Product Paclical Receives Market Approval InRead the original story

    Apr 19, 2015 | BioSpace

    Oasmia Pharmaceutical AB announced today that its lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health. Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization.

    Comment?

  17. Oasmia's Lead Cancer Product Paclical?? Receives Market Approval InRead the original story

    Apr 19, 2015 | BioSpace

    Oasmia Pharmaceutical AB announced today that its lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health. Paclical is the first water-soluble cancer drug with paclitaxel to receive a market authorization.

    Comment?

  18. Oasmia's lead cancer product Paclical receives market approval in the Russian FederationRead the original story w/Photo

    Apr 19, 2015 | GlobeNewswire

    April 20, 2015. Oasmia Pharmaceutical AB announced today that its lead cancer product Paclical received market authorization in the Russian Federation by the Russian Ministry of Health.

    Comment?

  19. A systems approach elucidates the mechanisms of action of traditional oriental medicineRead the original story w/Photo

    Mar 11, 2015 | Medical News Today

    A Korean research team at KAIST suggests that a systems approach using metabolite structural similarity helps to elucidate the mechanisms of action of traditional oriental medicine Traditional oriental medicine has been practiced in Asian countries for centuries, and is gaining increasing popularity around the world. Despite its efficacy in various symptoms, TOM has been practiced without precise knowledge of its mechanisms of action.

    Comment?

  20. A systems approach elucidates the mechanisms of action of traditional oriental medicineRead the original story w/Photo

    Mar 5, 2015 | EurekAlert!

    A Korean research team at KAIST suggests that a systems approach using metabolite structural similarity helps to elucidate the mechanisms of action of traditional oriental medicine IMAGE: The picture presents the structural similarity analysis of comparing compounds in traditional oriental medicine and those in all available approved drugs against the structures of human metabolites. view more Daejeon, Republic of Korea, March 6, 2015 -- Traditional oriental medicine has been practiced in Asian countries for centuries, and is gaining increasing popularity around the world.

    Comment?